Clinical Trial Update: Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants [Phase 3]

View source ↗

Summary

A Phase 3 lot-consistency study of the DTaP-IPV-HB-PRP~T vaccine administered at 2-4-6 months in healthy infants has completed; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTaP-IPV-HB-PRP-T vaccine (Diphtheria, Tetanus, acellular Pertussis, Inactivated Poliovirus, Hepatitis B, Haemophilus influenzae type b PRP-T vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED | Results posted: 2014-05-09